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Valvular Heart Disease
Determinants and Prognostic Significance of Exercise
Pulmonary Hypertension in Asymptomatic Severe
Aortic Stenosis
Patrizio Lancellotti, MD, PhD*; Julien Magne, PhD*; Erwan Donal, MD, PhD; Kim O’Connor, MD;
Raluca Dulgheru, MD; Monica Rosca, MD; Luc A. Pierard, MD, PhD
Background—Recent studies emphasized the usefulness of exercise stress echocardiography in asymptomatic patients with
aortic stenosis. Nevertheless, the additive value of exercise pulmonary hypertension (Ex-PHT) in such patients remains
unexplored. We therefore aimed to identify the determinants and to test the impact on outcome of Ex-PHT in asymptomatic
patients with severe aortic stenosis.
Method and Results—Asymptomatic patients with severe aortic stenosis (n105; aortic valve area 0.6 cm2/m2; age, 719
years; male, 59%) and preserved left ventricular systolic function (ejection fraction 55%) were prospectively submitted to
exercise stress echocardiography. Resting PHT and Ex-PHT were defined as a systolic pulmonary arterial pressure 50 and
60 mm Hg, respectively. Ex-PHT was more frequent than resting PHT (55% versus 6%; P0.0001). On multivariable
logistic regression, the independent predictors of Ex-PHT were male sex (odds ratio, 4.3; P0.002), resting systolic
pulmonary arterial pressure (odds ratio, 1.16; P0.002), exercise indexed left ventricular end-diastolic volume (odds ratio,
1.04; P0.026), exercise e-wave velocity (odds ratio, 1.35; P0.047), and exercise-induced changes in indexed left atrial
area (odds ratio, 1.36; P0.006). Ex-PHT was associated with reduced cardiac event-free survival (at 3 years, 227% versus
559%; P0.014). In a multivariable Cox proportional hazards model, Ex-PHT was identified as an independent predictor
of cardiac events (hazard ratio, 1.8; 95% confidence interval, 1.0–3.3; P0.047). When exercise-induced changes in mean
aortic pressure gradient were added to the multivariable model, Ex-PHT remained independently associated with reduced
cardiac event-free survival (hazard ratio, 2.0; 95% confidence interval, 1.1–3.6; P0.025).
Conclusions—In asymptomatic patients with severe aortic stenosis, the main determinants of Ex-PHT are male sex, resting
systolic pulmonary arterial pressure, and exercise parameters of diastolic burden. Moreover, Ex-PHT is associated with
a 2-fold increased risk of cardiac events. These results strongly support the use of exercise stress echocardiography in
asymptomatic aortic stenosis. (Circulation. 2012;126:851-859.)
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The management and the timing of surgery in asymptomaticpatients with severe aortic stenosis (AS) remain matters of
concern. In this setting, valve replacement is recommended
when the left ventricular (LV) ejection fraction (LVEF) is
reduced (50%). However, LVEF is often preserved in severe
AS as a result of adapted LV remodeling to the increased
afterload, often leading to late surgical referral. Furthermore,
recent studies have shown that irreversible LV myocardial
fibrosis may be present even when LVEF is preserved.1,2
Editorial see p 803
Clinical Perspective on p 859
A recent registry reported that compared with the conven-
tional treatment strategy (ie, wait for symptoms), early surgery in
patients with very severe AS was associated with an improved
long-term survival by decreasing cardiac mortality.3 However,
surgeons may be reluctant to operate on asymptomatic patients.
The risks of aortic valve surgery and late complications of
prosthesis need to be balanced against the possible prevention of
sudden death and lowering of cardiac mortality. Hence, early
elective surgery could be proposed to selected patients with a
high risk of rapid LV function deterioration or symptomatic
status impairment (ie, high risk of poor outcome).4,5 This
strategy requires the identification of accurate markers of poor
outcome. In this regard, the presence of pulmonary hypertension
(PHT) in patients with severe AS seems to be associated with a
poorer prognosis6,7 and a higher mortality rate after valve
replacement8 and represents an independent predictor of hospital
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mortality and postoperative major adverse cardiovascular and
cerebrovascular events.9 In patients receiving transcatheter aortic
valve implantation, PHT was a strong independent predictor of
poor outcome, augmenting by 2 the risk of late mortality.10
We have recently identified that exercise PHT in asymptom-
atic patients with primary mitral regurgitation was a good
marker of a high risk of reduced symptom-free survival. To the
best of our knowledge, the prognostic value of exercise PHT in
AS is still unknown. The aim of this study was to identify the
determinants and the potential prognostic importance of exercise
PHT in asymptomatic patients with severe AS.
Methods
We prospectively included consecutive patients with asymptomatic
severe AS (n195), defined as an aortic valve area indexed for body
size area 0.6 cm2/m2, and preserved LVEF (55%) who were
referred to our laboratory for exercise stress echocardiography. Only
patients with a normal exercise stress test (ie, truly asymptomatic
patients) were considered for the final analysis of the study, resulting
in the exclusion of 45 patients with abnormal exercise response. The
other exclusion criteria were (1) more than mild concomitant valvular
heart disease (n3), (2) atrial fibrillation (n2), (3) known pulmonary
disease (n1), (4) inability to perform an exercise test (n4), and (5)
the absence of measurable systolic pulmonary arterial pressure (SPAP)
at exercise (n35). The final population was composed of 105 patients
(age, 719 years; male, 59%). The baseline demographic and clinical
data were standardized and collected at the time of exercise
stress echocardiography.
Echocardiographic Study
Before the exercise stress test, resting comprehensive transthoracic
echocardiography was performed with the VIVID 7 ultrasound system
(General Electric Healthcare, Little Chalfont, UK). All Doppler echo-
cardiographic recordings were stored on a dedicated workstation for
subsequent offline analysis. For each measurement, at least 2 cardiac
cycles were averaged. Continuous-wave Doppler was used to measure
the aortic transvalvular maximal velocities; peak and mean gradients
were calculated with the simplified Bernoulli equation (P4v2, where
v is maximal aortic velocity in meters per second). LV stroke volume
was calculated by multiplying the LV outflow tract area by the LV
outflow tract velocity–time integral measured by pulsed-wave Doppler.
Aortic valve area was calculated with the continuity equation. The
biapical Simpson disk method was applied to quantify LV end-diastolic
and end-systolic volumes and EF. In addition to this conventional
evaluation of LV systolic function, 2-dimensional speckle tracking
analysis (2-dimensional strain) was performed to quantify global longi-
tudinal myocardial deformation as previously described.5,11 Briefly,
2-dimensional strain is a non–Doppler-based method using standard
2-dimensional images with a frame rate acquisition60 Hz. By tracing
the endocardial borders on an end-systolic frame, the software automat-
ically tracked the contour on the subsequent frames. Adequate tracking
was verified in real-time and was manually corrected when necessary.
The global longitudinal deformation strain represents the average of the
segment strains from the conventional apical 4-, 3-, and 2-chamber
views. Left atrial (LA) area was obtained by planimetry of an end-sys-
tolic frame from the apical 4-chamber view. Peak E- and A-wave
velocities of the mitral inflow were measured with pulsed-wave Dopp-
ler. Tissue Doppler imaging was applied for the measurement of the e
wave. The average of septal and lateral mitral annulus Ea-wave
velocities was used to calculate the E/e ratio.
SPAP was derived from the regurgitant jet of tricuspid regurgitation
using systolic transtricuspid pressure gradient and adding 10 mm Hg for
right atrial pressure as previously performed.12,13 Resting PHT and
exercise PHT were defined as SPAP 50 and 60 mm Hg, respec-
tively. Right atrial pressure was assumed to be constant from rest to
exercise.
Exercise Protocol
A symptom-limited graded maximum bicycle exercise test was
performed in the semisupine position on a tilt table. After an initial
workload of 25 W maintained for 2 minutes, the workload was
increased every 2 minutes by 25 W. A 12-lead ECG was monitored
continuously, and blood pressure was measured at rest and every 2
minutes during exercise. If patients were on -blockers, they were
asked to stop their medication 24 hours before the test. The other
medications, if any, were left unchanged. Patients with an abnormal
exercise test were excluded from the present study. Abnormal
exercise test was defined as (1) the occurrence of limiting breath-
lessness or fatigue at low workload (75 W); (2) the occurrence of
angina, dizziness, syncope, or near syncope; (3) a fall in systolic
blood pressure below baseline or a rise in systolic blood during
exercise20 mm Hg; (4) 2-mm ST-segment depression compared
with baseline levels; and (5) complex ventricular arrhythmia.
Event-Free Survival
Follow-up information was obtained every 6 to 12 months from
standardized interviews with the patients, their physicians, or, if
necessary, their next of kin according to guidelines.14,15 The primary
outcome variable was the time to occurrence of the first composite
end point defined as cardiovascular death or need for aortic valve
replacement motivated by the development of symptoms or LV
systolic dysfunction. The patients’ personal physicians determined
the clinical management of the patients independently.
Statistical Analysis
Results are expressed as meanSD or percentage unless otherwise
specified. Data comparisons were performed according to the pres-
ence or absence of exercise PHT using the Student unpaired t test, 2
test, or Fisher exact test as appropriate. The prevalence of PHT at rest
and during exercise was compared by use of McNemar test. The
significant changes from rest to exercise in continuous variables were
assessed with a paired t test. The relationships between exercise SPAP
and other continuous variables (ie, demographic data, exercise data, and
resting and exercise echocardiographic data) were evaluated by simple
linear regression. Independent predictors of exercise SPAP were ob-
tained with the use of stepwise multiple linear regression. Predictors of
exercise PHT were determined with stepwise logistic regression. In both
multiple linear regression and logistic regression, variables with a
univariable value of P0.10 were incorporated into the multiple
regression; then, variables with a value of P0.20 were removed.
Sensitivity, specificity, positive predictive value, and negative predictive
value for the prediction of the occurrence of cardiac event were
determined for various cutoff values of exercise SPAP with receiver-
operating characteristic curves.
Probabilities of event-free survival were obtained by Kaplan-
Meier estimates for the 2 groups and then compared by a 2-sided
log-rank test.
The impact of exercise PHT on event-free survival was assessed
with Cox proportional hazards models in univariable and multivari-
able analyses. Variables with a univariable value of P0.10 were
incorporated into the multivariable models. The selection of vari-
ables included in the multivariate model was performed with special
care. To avoid collinearity among a subset of several variables
measuring the same phenomenon (eg, aortic valve area, peak
gradient, mean gradient), we entered into the multivariate models the
variable that had the strongest association with event-free survival on
univariable analysis. In addition, to assess the accuracy of the
prediction of a cardiac event by each model, we generated the Harrell
correspondence index (C statistic).
Values of P0.05 were considered significant. All statistical
analyses were performed with STATISTICA version 7 (StatSoft Inc,
Tulsa, OK).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the manuscript
as written.
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Results
Population Characteristics
PHT, as previously defined, was significantly more frequent
during exercise (55% versus 6%; P0.0001) than at rest.
Patients with exercise PHT were more frequently male and had
significant lower resting heart rate than those with no exercise
PHT (Table 1). In addition, all patients with resting PHT (n6;
Table 2) also developed exercise PHT (P0.027, resting PHT
prevalence in exercise PHT versus the no exercise PHT group).
There was no other significant difference between the 2 groups
in terms of demographic, clinical, or exercise data, as well as risk
factors and medications. The maximal exercise capacity reached
was 4.81.2 metabolic equivalents (METs; 6414% of the
predicted METs), ranging from 2.3 to 8.6 METs with no
significant difference between the 2 groups (P0.12 and
P0.74 for the percentage of predicted METs).
Resting and Exercise Echocardiography
SPAP significantly increased from rest to exercise (from 388
to 6216 mm Hg; P0.0001). Patients with exercise PHT
had significant higher resting SPAP (P0.0001; Table 2)
and exercise-induced changes in SPAP (14.97 versus
33.610 mm Hg; P0.0001; Figure 1A and 1B). In patients
with exercise PHT, the mean relative change in SPAP was
12161%. During exercise, SPAP was doubled in 10 patients
(21%) without exercise PHT and in 32 patients (56%;
P0.0001) with exercise PHT.
Compared with patients with no exercise PHT, those with
exercise PHT (Table 2) had higher resting and exercise
indexed LV end-diastolic volume (P0.045 and P0.04)
and more severe resting and exercise AS (peak transaortic
gradient, P0.046 and P0.008; mean transaortic gradient,
P0.04 and P0.04), higher exercise e-wave velocity
(P0.004), and larger exercise indexed LA area (P0.001).
There were also trends for significantly higher resting and
exercise E-wave velocity (P0.10 and P0.07) and exercise
indexed LV end-systolic volume (P0.07).
Determinants of Exercise SPAP and PHT
In simple linear regression, exercise SPAP was significantly
correlated with resting SPAP (r0.57, P0.0001), heart rate
(r0.20, P0.045), E-wave velocity (r0.19, P0.05),
exercise e-wave velocity (r0.19, P0.009), and indexed
LV end-diastolic volume (r0.17, P0.044). Both resting
and exercise peak (r0.23, P0.02; and r0.29, P0.003)
and mean (r0.23, P0.016; and r0.24, P0.013) transaortic
pressure gradients were significantly correlated with exercise
SPAP. In addition, the best correlation was found between
exercise SPAP and exercise-induced changes in indexed LA
area (r0.40, P0.0001). Multiple linear regression revealed
that the independent predictors of exercise SPAP were exercise
e-wave velocity (115; P0.046), exercise indexed LV
end-diastolic volume (0.140.07; P0.038), resting SPAP
(0.90.2; P0.0001), and exercise-induced changes in in-
dexed LA area (1.30.4; P0.001).
On multivariable analysis, with logistic regression (Table
3), the independent predictors of exercise PHT were male sex
(odds ratio, 4.3; P0.002), resting SPAP (odds ratio, 1.16;
P0.002), exercise indexed LV end-diastolic volume (odds
ratio, 1.04; P0.026), exercise e-wave velocity (odds ratio,
Table 1. Demographic, Clinical, and Exercise Data
Variables
Whole Cohort
(n105)
No Exercise PHT
(n47, 45%)
Exercise PHT
(n58, 55%) P
Demographic and clinical data
Age, y 719 717 719 0.77
Male sex, n (%) 62 (59) 23 (49) 39 (67) 0.03
Body surface area, m2 1.80.2 1.80.2 1.80.2 0.81
Heart rate, bpm 7113 7314 6812 0.04
Systolic arterial pressure, mm Hg 14220 13919 14420 0.13
Diastolic arterial pressure, mm Hg 7611 7612 7710 0.64
Risk factors, n (%)
Hypertension 69 (66) 28 (60) 41 (71) 0.21
Overweight 36 (34) 15 (32) 21 (36) 0.68
Dyslipidemia 54 (51) 24 (51) 30 (52) 0.94
Diabetes mellitus 18 (17) 9 (19) 9 (16) 0.68
Smoker 35 (33) 14 (30) 21 (36) 0.63
LV hypertrophy 51 (49) 27 (57) 25 (43) 0.14
Exercise data
Maximal exercise capacity, METS 4.81.2 4.60.8 4.91.3 0.12
Percentage of predicted exercise capacity, % 6414 6412 6315 0.74
Heart rate, bpm 11917 11817 11917 0.62
Systolic arterial pressure, mm Hg 17722 17420 17923 0.20
Diastolic arterial pressure, mm Hg 8614 8515 8713 0.52
PHT indicates pulmonary arterial hypertension; LV, left ventricular; and MET, metabolic equivalents.
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1.35; P0.047), and exercise-induced changes in indexed LA
area (odds ratio, 1.36; P0.006).
Cardiac Event-Free Survival
The follow-up was complete in all patients (100%). The mean
follow-up time was 1911 months (median, 16 months;
range, 2–48 months). During follow-up, 56 patients (53%)
fulfilled the predefined end point, resulting in event-free
survival of 724%, 505%, and 346% at the 1-, 2-, and
3-year follow-up, respectively. There were 7 cardiovascular
deaths during the follow-up (3 sudden deaths and 4 deaths
after heart failure hospitalization). Of note, the 7 patients who
died had developed exercise PHT (12%), but only 1 had
resting PHT (P0.014). The remaining cardiac events were
aortic valve replacement dictated by the onset of symptoms
(n49). The main indication for surgery was the occurrence
of syncope (n4), angina (n6), dyspnea (n38), and
significant arrhythmia (n1).
During the follow-up, among the 6 patients with resting
PHT, 1 died, 2 underwent an aortic valve replacement, and 3
remained free of event.
The raw rate of cardiac event (number of patients with an
event divided by total number of patients in each group) was
significantly higher in patients with exercise PHT (n39
versus n17, 67% versus 36%; P0.0015).
Patients with exercise PHT had lower cardiac event-free
survival (at 1 year, 656% versus 816%; at 2 years, 437%
versus 598%; at 3 years, 227% versus 559%; P0.014;
Table 2. Resting and Exercise Echocardiographic Data
Variables
Whole Cohort
(n105)
No Exercise PHT
(n47, 45%)
Exercise PHT
(n58, 55%) P
Resting LV function
Indexed LV end-systolic volume, mL/m2 1910 199 2011 0.64
Indexed LV end-diastolic volume, mL/m2 5417 5115 5718 0.045
LV ejection fraction, % 677.6 667.5 67.57.7 0.40
LV global longitudinal strain, % 16.32.6 16.32.5 16.22.7 0.82
E-wave velocity, cm/s 0.800.2 0.760.2 0.840.2 0.10
A-wave velocity, cm/s 0.930.3 0.890.3 0.970.3 0.23
e-wave velocity, cm/s 7.82.2 7.61.8 8.02.5 0.35
E/A ratio 0.920.4 0.900.3 0.940.4 0.64
E/e ratio 10.93.6 10.43.1 11.24.1 0.28
Exercise LV function
Indexed LV end-systolic volume, mL/m2 188.3 177.3 208.9 0.07
Indexed LV end-diastolic volume, mL/m2 5417 5015 5719 0.04
LV ejection fraction, % 679 678 6610 0.41
E-wave velocity, cm/s 1.270.3 1.220.3 1.330.3 0.07
A-wave velocity, cm/s 1.010.3 0.980.3 1.050.3 0.43
e-wave velocity, cm/s 10.12.7 9.22.1 10.83.0 0.004
E/A ratio 1.350.6 1.250.4 1.440.8 0.25
E/e’ ratio 13.45.2 13.34.6 13.46.0 0.94
Resting aortic stenosis severity
Peak transaortic gradient, mm Hg 7223 6719 7626 0.046
Mean transaortic gradient, mm Hg 4515 4212 4716 0.04
Aortic valve area, cm2 0.890.1 0.880.1 0.900.1 0.59
Indexed aortic valve area, cm/m2 0.500.1 0.490.1 0.500.1 0.63
Exercise aortic stenosis severity
Peak transaortic gradient, mm Hg 9128 8321 9731 0.008
Mean transaortic gradient, mm Hg 5718 5314 6020 0.04
Aortic valve area, cm2 0.970.3 0.950.2 0.990.3 0.41
Indexed aortic valve area, cm/m2 0.540.16 0.530.1 0.550.2 0.46
Resting indexed LA area, cm2/m2 12.53.4 12.74 12.33 0.64
Exercise indexed LA area, cm2/m2 11.23.6 9.83.6 12.23.4 0.001
Resting PHT, n (%) 6 (6) 0 (0) 6 (10) 0.027
Resting SPAP, mm Hg 388 346 418 0.0001
Exercise SPAP, mm Hg 6216 489 749 0.0001
PHT indicates pulmonary arterial hypertension; LV indicates left ventricular; LA, left atrial; and SPAP, systolic pulmonary arterial
pressure.
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Figure 2). In univariable analysis, exercise PHT was associated
with 2-fold increase in cardiac events compared with patients
without exercise PHT (P0.017; Table 4). Other univariable
predictors of cardiac event were peak aortic jet velocity (hazard
ratio [HR], 2; 95% confidence interval [CI], 1.35–2.97;
P0.001), mean aortic transvalvular gradient (HR, 1.03; 95%
CI, 1.01–1.04; P0.02), LV filling time (HR, 1.01; 95% CI,
1.00–1.01; P0.014), indexed LV end-systolic volume (HR,
1.03; 95% CI, 1.01–1.05; P0.018), indexed LV end-diastolic
volume (HR, 1.02; 95% CI, 1.01–1.04; P0.002), and indexed
LA area (HR, 1.06; 95% CI, 1.00–1.13; P0.049). Of note,
exercise capacity, as assessed by the maximal reached METs,
was not associated with reduced cardiac-event free survival (HR,
1.83; 95% CI, 0.7–4.8; P0.21), and none of the other exercise
parameters was associated with outcome.
Resting PHT (n6) was not associated with reduced cardiac
event-free survival (P0.37). However, there was a significant
relationship between resting SPAP and outcome (HR, 1.03; 95%
CI, 1.00–1.06; P0.03). This relationship remained significant
after adjustment for age and sex (HR, 1.04; 95% CI, 1.00–1.07;
P0.03) but not after adjustment for peak or mean aortic
transvalvular gradient (HR, 1.03; 95% CI, 0.99–1.06; P0.135;
and HR, 1.03; 95% CI, 0.99–1.06; P0.08, respectively).
Further adjustment with other resting echocardiographic data led
to a definite nonsignificant association between resting SPAP
and cardiac event-free survival (HR, 1.03; 95% CI, 0.99–1.07;
P0.15).
After adjustment for age and sex, exercise PHT was indepen-
dently associated with reduced cardiac event-free survival (HR,
1.9; 95% CI, 1.1–3.4; P0.025; Table 4). With further adjust-
ment including resting echocardiographic data, exercise PHT
remained independently associated with cardiac events (HR, 1.8;
95% CI, 1.0–3.3; P0.047). As previously reported, exercise-
induced changes in mean transaortic pressure gradient were
associated with reduced event-free survival (HR, 1.02; 95% CI,
1.01–1.03; P0.003). In the multivariable model (Table 4), after
adjustment for age, sex, resting echocardiographic data, and
exercise-induced changes in mean transvalvular pressure gradi-
ent, exercise PHT remained an independent predictor of high
risk of cardiac events (HR, 2.0; 95% CI, 1.1–3.6; P0.025). Of
note, in this multivariable model, exercise-induced change in
mean transaortic pressure gradient was also an independent
predictor of events (P0.043).
Figure 1. Impact of exercise on systolic pulmonary arterial pressure in patients without exercise pulmonary hypertension (A) and with
exercise pulmonary hypertension (B).
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Figure 2. Cardiac event-free survival according to the presence
or absence of exercise pulmonary hypertension (PHT).
Table 3. Logistic Regression: Independent Determinants of
Exercise Pulmonary Arterial Hypertension
Variables Odds Ratio 95% CI P
Male sex 4.3 1.2–15.1 0.002
Resting SPAP (per mm Hg) 1.16 1.06–1.27 0.002
Exercise indexed LV end-diastolic
volume (per mL/m2)
1.04 1.00–1.07 0.026
Exercise-induced changes in indexed
LA area (per cm2/m2)
1.36 1.1–1.7 0.006
Exercise e-wave velocity (per cm/s) 1.35 1.00–1.8 0.047
CI indicates confidence interval; SPAP, systolic pulmonary arterial pressure;
LV, left ventricular; and LA, left atrial. Adjustment performed with age, resting
heart rate, resting mean transaortic pressure gradient, exercise peak transaor-
tic pressure gradient, exercise e-wave velocity, and exercise indexed LV
end-systolic volume.
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Using receiver-operating characteristic curve analysis, we
found that exercise SPAP had a good accuracy for predicting
cardiac events (area under the curve, 0.69). Of interest, the
best cutoff value to predict cardiac events was exercise SPAP
60 mm Hg: sensitivity, 70%; specificity, 62%; positive
predictive value, 67%; and negative predictive value, 64%.
In addition, to assess whether exercise SPAP was more
accurate than resting SPAP in predicting cardiac events, we
generated the C statistic for each model. The C statistics were
systematically higher with exercise SPAP than resting SPAP
in univariate age- and sex-adjusted or age-, sex-, and resting
echocardiographic data–adjusted models (0.610 versus 0.515,
0.613 versus 0.557, and 0.664 versus 0.611, respectively).
Incremental Prognostic Value of Exercise PHT
Over Resting AS Severity
In the whole multivariate model, peak aortic jet velocity was
the strongest resting echocardiographic predictor of outcome
(HR, 1.02; 95% CI, 1.01–1.03; P0.0001). Figure 3 shows
the incremental value of exercise PHT over markedly elevated
peak aortic jet velocity (4.0 m/s) in the prediction of cardiac
events. The combination of high peak aortic jet velocity and
exercise PHT resulted in the worse outcome (P0.008). Com-
pared with the whole cohort, patients with high peak aortic jet
velocity and exercise PHT had a 2.4-fold increased risk of
reduced event-free survival (95% CI, 1.4–4.03; P0.002).
Reducing the analysis only to the subset of patients with
markedly elevated peak aortic jet velocity resulted in a signifi-
cant impact of exercise PHT on outcome (HR, 2.4; 95% CI,
1.1–5.2; P0.014). Of note, patients with exercise PHT but
without markedly elevated peak aortic jet velocity had a 2-year
event-free survival (5410% versus 5611%; P0.77) similar
to that of patients with markedly elevated peak aortic jet velocity
but without exercise PHT. Furthermore, the 7 deaths occurring
during the follow-up were in patients with both markedly
elevated peak aortic jet velocity and exercise PHT (P0.001).
Discussion
The main findings of the present study are that (1) exercise
PHT (ie, exercise SPAP 60 mm Hg) is a frequent condition
(55% of the cohort) in patients with asymptomatic severe AS
and preserved LVEF; (2) the independent determinants of
exercise PHT are male sex, resting SPAP, and exercise param-
eters of diastolic burden (exercise indexed LV end-diastolic
volume, exercise e-wave velocity, and exercise-induced
changes in indexed LA area); (3) exercise PHT is associated
with an alarming rate of cardiac death (12%) and with significant
reduced cardiac event-free survival; (4) exercise PHT doubles
the risk of cardiac events independently of age, sex, resting
echocardiographic data, and exercise-induced changes in mean
transaortic pressure gradient; and (5) exercise PHT had an
incremental prognostic value compared with resting AS severity
parameter. Conversely, although resting elevated SPAP may
affect clinical outcome, its prognostic value was weak in our
study.
Pulmonary Arterial Hypertension in AS
The prevalence of PHT varies considerably over studies
according to patient selection criteria and the threshold used
to define PHT. Overall, an SPAP 50 mm Hg is found in
15% to 30% of patients with severe AS,16–18 and recently,
severe SPAP (60mmHg) was reported in 19% of a large
cohort of 626 AS patients.19
Table 4. Cox Proportional Hazards Regression Analysis for
the Prediction of Cardiac Event-Free Survival
Models
Exercise PHT
Hazard Ratio 95% CI P
Univariable 2.0 1.1–3.5 0.017
Age and sex adjusted 1.9 1.1–3.4 0.025
Resting data adjusted* 1.8 1.1–3.3 0.045
Exercise data adjusted† 2.0 1.1–3.6 0.025
PHT indicates pulmonary arterial hypertension; CI, confidence interval.
*Adjustment including age, sex, indexed left atrial area, left ventricular
end-systolic volume, left ventricular end-diastolic volume, E/e ratio, and peak
aortic jet velocity.
†Adjustment including age, sex, resting echocardiographic data, and
exercise-induced changes in mean transaortic pressure gradient.
Figure 3. Cardiac event-free survival according to
the presence or absence of exercise pulmonary
hypertension (Ex. PHT) and markedly elevated
peak aortic (Ao) jet velocity (4 m/s).
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However, to the best of our knowledge, no study has
reported the prevalence of PHT in truly asymptomatic pa-
tients. In our cohort, an SPAP 50 mm Hg was rare and
identified in only 6 patients (6%), suggesting that the impact
of severe AS on LV diastolic function20 and LA geometry and
function21,22 may be generally well counterbalanced by LA
compliance and/or pulmonary vascular resistance. Of interest,
these patients with resting PHT were particularly old and had
very severe AS, and half of them experienced cardiac events
(including 1 death and 2 aortic valve replacement), suggest-
ing the poor outcome of this subset. In contrast, a recent study
has shown that PHT is frequent in surgery-referred patients
with LV dysfunction and is independently associated with LA
function impairment.23
The potential impact on outcome of PHT in patients with
AS is also a source of debate. In 1979, McHenry et al7
showed that PHT could be considered a harbinger for sudden
death and clinical deterioration. More recently, PHT in severe
AS was also associated with a dismal prognosis under
conservative management.24,25 Nevertheless, PHT may fre-
quently and rapidly be abolished after aortic valve replace-
ment,24–26 leading to a more favorable long-term outcome.27
Exercise PHT in AS
Exercise PHT was significantly more frequent (55%) than
resting PHT (6%) in our cohort. This entity is characterized
by lower resting heart rate and higher resting and peak
exercise indexed LV end-diastolic volume. During exercise,
whereas some patients with no exercise PHT may have only
a mild increase in SPAP (Figure 1A), the vast majority of
those with exercise PHT (Figure 1B) experienced a marked
rise in SPAP. This phenomenon is essentially determined by
the level of exercise e-wave velocity, the exercise indexed
LV end-diastolic volume, and the exercise-induced changes
in indexed LA area.
In AS, the chronically increased afterload results in progres-
sive LV remodeling and myocardial hypertrophy. Although the
increase in LV wall thickness is a compensatory mechanism that
reduces systolic wall stress, it can result in impaired LV
relaxation, reduced LV compliance, and increased metabolic
demands. The ability of the LV to adequately fill under normal
pressures is thus altered and the LV diastolic pressure increases.
As a result, LA slowly expands and becomes dysfunctional and
less compliant, making it impossible to limit the transmission to
the pulmonary vascular bed of any further increase, even
minimal, in LV end-diastolic pressure observed during exercise.
Furthermore, any degree of LV diastolic dysfunction (relaxation
abnormality) and increased LV filling pressure at rest and/or at
exercise can be sufficient to trigger exercise PHT. In these
patients, exercise echocardiography enables us to unmask a
more advanced impairment in LV diastolic properties, namely
latent LV diastolic dysfunction. This is line with our observa-
tions because exercise PHT was related mainly to exercise
parameters of diastolic burden. Of note, a limitation in LA
compliance was confirmed by the significant correlation ob-
served between exercise-induced changes in indexed LA area
and exercise SPAP. For a given increase in LV filling pressure,
patients with limited changes in LA dimensions (ie, exhausted
LA compliance reserve) during exercise displayed a higher
increase in SPAP; this is even truer if LA emptying is not
facilitated any more from recruitable LA function.
Clinical Implications
Our results are the first to demonstrate that the measurement
of SPAP during exercise echocardiography may improve risk
stratification of asymptomatic severe AS. Indeed, patients who
experienced exercise PHT (SPAP60 mm Hg) multiplied by 2
the risk of cardiac events, even after adjustment for demographic
and resting and exercise echocardiographic data. Among the 7
cardiovascular-related deaths that occurred during follow-up,
only 1 patient had resting PHT, but all of those patients had
developed exercise PHT. Of interest, our data show that resting
elevated SPAP is not independently associated with reduced
cardiac event-free survival in “truly” asymptomatic patients with
severe AS.
Hence, these results strongly emphasize the usefulness of
exercise stress echocardiography in this clinical situation. Exer-
cise PHT also had incremental prognostic value compared with
AS severity parameters (ie, aortic jet velocity). Indeed, in
patients with markedly elevated aortic jet velocity, those with
exercise PHT exhibited a significant lower cardiac event-free
survival (Figure 3) compared with the others, resulting in poorer
outcome. Furthermore, patients with exercise PHT but without
markedly elevated aortic jet velocity had a prognosis similar to
that for those without exercise PHT but with high aortic jet
velocity. Thus, in patients with asymptomatic AS and 4-m/s
aortic jet velocity, the presence of exercise PHT is still able to
identify a subset of patients at dismal prognosis (Figure 3) who
may require a closer follow-up to look for any changes in LV
diastolic function and symptoms.
During tests, an exercise-induced increase in mean transaortic
pressure gradient by 18 to 20 mm Hg has recently been
identified as a marker of poor prognosis in asymptomatic
AS.28,29 Our results confirm that this parameter is associated
with reduced cardiac event-free survival, but we further show
that exercise PHT is an predictor of impaired prognosis inde-
pendently of the changes in LV afterload. Interestingly, only one
third of patients with exercise PHT also had a marked increase
in mean transaortic pressure gradient. This suggests that the
presence of elevated exercise SPAP may unmask a subset of
asymptomatic patients with latent LV diastolic dysfunction,
reduced atrioventricular compliance, and impaired pulmonary
vascular resistance. These patients are probably more subject to
rapidly developing symptoms and seem to be at higher risk of
cardiac-related death. Consequently, the use of exercise stress
echocardiography in asymptomatic patients with severe AS
could be recommended. At peak exercise, the measurement of
both mean transaortic pressure gradient and SPAP, which are
technically easy and rapid and have good reproducibility,13,29–32
may improve the management of such patients. Indeed, the high
rate of cardiac-related death observed in patients with exercise
PHT (12%), despite normal exercise tests, should encourage
prompt surgery, which is, in asymptomatic patients, associated
with very low operative mortality3 and low prosthesis-related
complication rate. Conversely, patients with no exercise PHT
and no marked increase in mean transaortic gradient can be
followed up safely.
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Limitations
Apparent nonsignificant results may be related to the relatively
small sample size of the study. Specifically, the absence of
relationship between maximal exercise capacity parameters and
cardiac event-free survival could be due mainly to a type II error.
Nevertheless, this limitation does not affect the validity of the
main result of the study, which is the demonstration that exercise
PHT may have an incremental prognostic value in patients with
asymptomatic severe AS.
Despite careful assessment, the evaluation of the occur-
rence of symptoms at a low workload during exercise remains
subjective. Hence, although rare, it is possible that some
patients with symptoms during exertion were included in the
final population.
As in our previous studies,13,33 the right atrial pressure was
estimated at 10 mm Hg both at rest and during exercise.
Hence, we may have missed the potential influence of
exercise-induced changes in right atrial pressure. Neverthe-
less, the noninvasive evaluation of right atrial pressure during
exercise (ie, when venous compliance is known to decrease)
with noninvasive methods such as Doppler echocardiography
remains difficult, is probably subject to low accuracy, and is
not validated. Moreover, right atrial pressure is frequently
assumed to be 5 mm Hg in normal subjects30 and 10 mm Hg
in patients with valvular disease.12
The absence of evaluation of the presence and extent of
coronary artery disease in patients not referred to surgery is
also a limitation of this report. However, these patients have,
by definition, no resting symptoms and normal LVEF and
exercise test, suggesting that they are truly asymptomatic. In
this context, coronary angiography is not recommended, and
the rate of significant coronary artery disease in our popula-
tion is probably low.
Conclusions
In asymptomatic patients with severe AS, the main determinants
of exercise PHT are male sex, resting SPAP, and exercise
parameters of diastolic burden. Exercise PHT is associated with
a 2-fold increased risk of cardiac events and provides incremen-
tal prognostic value independently of demographic, resting
echocardiographic data, and exercise-induced changes in mean
transaortic pressure gradient. These results support the use of
exercise stress echocardiography in asymptomatic AS.
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CLINICAL PERSPECTIVE
The management and timing of surgery in asymptomatic patients with severe aortic stenosis remain matters of concern. The
risks of aortic valve surgery and late complications of prosthesis in such patients need to be balanced against the possible
prevention of sudden death and lowering of cardiac mortality. Hence, early elective surgery could be proposed only to
well-selected patients considered at high risk of poor outcome. In the present study, 105 consecutive asymptomatic patients
with severe aortic stenosis underwent comprehensive resting and exercise stress echocardiography to evaluate the presence
of pulmonary hypertension (PHT). The results showed that 55% of asymptomatic patients may develop exercise PHT.
Patients with exercise PHT had significantly lower cardiac event-free survival and a markedly higher rate of death than
those without exercise PHT. In addition, exercise PHT was associated with poorer outcome independently of demographic
and resting echocardiographic data and exercise-induced changes in mean transaortic pressure gradient. Beyond both
resting aortic stenosis severity and systolic pulmonary arterial pressure, the assessment of the presence of exercise PHT
provided important incremental predictive value. Even in patients with markedly elevated aortic jet velocity, those with
exercise PHT depicted a higher risk of reduced cardiac event-free survival. These results strongly support the use of
exercise stress echocardiography in the management of asymptomatic severe aortic stenosis. Early elective aortic valve
surgery to prevent irreversible left ventricular myocardial damage, diastolic dysfunction, and symptoms could be advised
in patients developing exercise PHT. In contrast, asymptomatic patients with no exercise PHT may be conservatively
followed up.
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summary
배경
최근 연구 결과에서 무증상의 대동맥판협착증 환자에
서 운동 심초음파(exercise stress echocardiography) 
검사의 유용성이 증명된 바 있다. 하지만 이들 환자에
서 운동시 폐고혈압의 의미에 대해서는 알려진 바가 
별로 없다. 본 연구의 저자들은 무증상의 중증 대동맥
판협착증 환자에서 운동시 폐고혈압의 결정인자와 예
후에 대한 영향을 알아보고자 하였다. 
방법 및 결과 
증상이 없으면서 좌심실 수축기능이 정상인(구혈률 
≥55%) 중증 대동맥판협착증 환자(총 105명, 대동맥
판 면적 <0.6cm2/m2; 평균 연령 71±9세; 남성 59%)를 
전향적으로 모집하여 운동 심초음파 검사를 시행하였
다. 안정시 및 운동시 폐고혈압은 각각 폐동맥 수축기
압 >50mmHg와 >60mmHg를 기준으로 하였다. 운
동시 폐고혈압은 안정시보다 흔하게 관찰되었다(55% 
vs. 6%; P<0.0001). 다변량 로지스틱 회귀분석에서 운
동시 폐고혈압의 독립적인 예측인자는 남성(OR 4.3; 
P=0.002), 안정시 폐동맥 수축기압(OR 1.16; P=0.002), 
운동시 좌심실 이완기말 용적(OR 1.04; P=0.026), 운동
시 e’-파 속도(OR 1.35; P=0.047), 그리고 운동시 좌심
방 면적의 변화였다(OR 1.36; P=0.006). 운동시 폐고혈
압은 심혈관계 사건-free survival 감소와 관련 있었다
(3년 후, 22±7% vs. 55±9%; P=0.014). 또한, 다변량분
석에서 운동시 폐고혈압은 심혈관계 사건의 독립적인 
예측인자였다(HR, 1.8; 95% CI 1.0-3.3; P=0.047). 운
동시 대동맥판 압력차 상승을 다변량분석에 포함시키
면, 운동시 폐고혈압은 심혈관계 사건-free survival 저
하와 독립적으로 관련되었다(HR, 2.0; 95% CI 1.1-3.6: 
P=0.025). 
결론 
무증상의 중증 대동맥판협착증 환자에서 운동시 폐고
혈압의 주요 결정인자는 남성, 안정시 폐동맥 수축기
압, 운동시 이완기 지표들이었다. 운동시 폐고혈압은 심
혈관계 사건 발생 위험의 2배 증가와 관련있었다. 이런 
결과들은 무증상의 대동맥판협착증 환자에서 운동 심
초음파 검사의 유용성을 잘 보여준다.
운동시 폐고혈압은 무증상 대동맥판협착증의 
새로운 위험신호이다
김	용	진	교수	서울대학교병원 순환기내과
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commentary
중증 대동맥판협착증에 의한 좌심실의 압력 과부하는 
좌심실비대와 섬유화를 유발하고, 관상동맥의 확장능
을 감소시켜 좌심실의 수축 및 이완 기능장애를 초래
하며, 궁극적으로는 호흡곤란, 흉통, 실신의 증상을 유
발하고, 더 진행되면 사망에 이르게 된다. 증상이 발생
하면 수술만이 증상과 좌심실 기능, 생존율을 개선시
킬 수 있기 때문에 치료전략은 간단하다. 하지만 증상
이 없는 환자에서 수술의 적응증에 대해서는 아직 논
란이 많다. 현재까지의 가이드라인에서는 주의 깊은 관
찰을 권고하고 있지만, 많은 연구를 통해 결국 3-5년 
이내에 증상이 발생하거나 수술을 시행하게 되는 환자
들이 적지 않다는 것이 잘 알려져 있으며, 일부 연구에
서는 무증상 환자에서도 사망의 위험이 증가한다고 보
고하고 있다. 대동맥판막 수술에 따른 위험도가 낮기 
때문에, 최근 들어 무증상 환자 중 사망이나 증상 발생
의 위험이 큰 군을 찾아 조기 수술을 시행하고자 하는 
전문병원의 노력이 많은 주목을 받고 있다. 
대동맥판협착증 환자에서 증상 유무를 제대로 평가하
는 것은 때로는 쉽지 않다. 적지 않은 환자들이 증상에 
맞게 활동량을 줄이기 때문에 증상이 없는 것으로 오
인될 수 있으며, 또한, 고령, 운동 부족, 과체중 환자에
서 흔히 보이는 경도의 호흡곤란을 심장질환에 의한 
것으로 판단하는 데도 많은 어려움이 있다. 따라서 운
동검사는 위험도가 높은 환자에서 증상 유무와 정상적
인 혈압 반응을 평가하는 데 좋은 방법으로 제시되어 
왔다. 즉, 운동검사에서 운동능력이 저하되어 있거나 
혈압이 적절히 상승하지 않는 환자들이 수년 내에 증
상이 발생하거나 수술을 받게 될 가능성이 높다는 것
이다. 하지만 이런 연구들은 운동검사 결과 자체가 향
후 치료방침을 결정하는 데 영향을 미칠 수 있으며, 증
상의 원인이 심장인지 아닌지를 감별하는 데에도 주관
적일 수밖에 없었다. 
운동 심초음파검사는 도플러 에코를 통해 운동시 혈
역학적 변화를 평가할 수 있기 때문에 일반적인 운
동검사에 비해 객관적인 수치를 제시할 수 있다는 장
점이 있다. 과거 연구에서 운동시 대동맥판 압력차가 
20mmHg 이상 증가하는 환자에서 향후에 증상이 발
생하거나 사망할 가능성이 높았다. 
본 연구에서 저자들은 기존에 알려진 운동시 대동맥
판 압력차 외에 폐동맥 수축기압의 변화를 측정하여 
운동시 폐고혈압이 발생하는 환자에서 수술, 심부전, 
사망의 발생률이 높다는 것을 보고하였다. 특히, 운
동능력이 저하되어 있거나(75W 미만), 운동 중 혈압
이 20mmHg 이상 적절히 상승하지 않거나, ST분절이 
2mm 이상 하강하는 이상반응을 보이는 환자들은 모
두 제외했기 때문에 새로운 위험인자로서의 임상적 의
의가 크다고 하겠다. 또한, 본 연구에서 폐동맥 수축기
압의 상승은 좌심실의 이완기능이나 좌심방 크기와 연
관되었는데, 이는 운동시 폐고혈압이 대동맥판협착증
에 의한 좌심실의 변화를 잘 나타낸다고 하겠다. 
하지만 본 연구의 결과가 곧 운동시 폐고혈압을 보이
는 환자에서 조기수술이 필요하다는 의미는 아니다. 
즉, 운동시 폐고혈압이 발생한 환자에서 위험도가 높았
지만, 이 환자들에서 조기수술을 시행하는 것이 예후
를 개선할 수 있다는 증거가 될 수는 없다. 따라서 향후 
무증상의 중증 대동맥판협착증 환자에서 다양한 위험
도 평가 방법을 개발하고, 그에 따른 조기수술이 예후
에 미치는 영향에 대한 대규모 전향적 연구가 필요하
겠다.   
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Valvular Heart Disease
Determinants and Prognostic Significance of Exercise
Pulmonary Hypertension in Asymptomatic Severe
Aortic Stenosis
Patrizio Lancellotti, MD, PhD*; Julien Magne, PhD*; Erwan Donal, MD, PhD; Kim O’Connor, MD;
Raluca Dulgheru, MD; Monica Rosca, MD; Luc A. Pierard, MD, PhD
Background—Recent studies emphasized the usefulness of exercise stress echocardiography in asymptomatic patients with
aortic stenosis. Nevertheless, the additive value of exercise pulmonary hypertension (Ex-PHT) in such patients remains
unexplored. We therefore aimed to identify the determinants and to test the impact on outcome of Ex-PHT in asymptomatic
patients with severe aortic stenosis.
Method and Results—Asymptomatic patients with severe aortic stenosis (n�105; aortic valve area �0.6 cm2/m2; age, 71�9
years; male, 59%) and preserved left ventricular systolic function (ejection fraction �55%) were prospectively submitted to
exercise stress echocardiography. Resting PHT and Ex-PHT were defined as a systolic pulmonary arterial pressure �50 and
�60 mm Hg, respectively. Ex-PHT was more frequent than resting PHT (55% versus 6%; P�0.0001). On multivariable
logistic regression, the independent predictors of Ex-PHT were male sex (odds ratio, 4.3; P�0.002), resting systolic
pulmonary arterial pressure (odds ratio, 1.16; P�0.002), exercise indexed left ventricular end-diastolic volume (odds ratio,
1.04; P�0.026), exercise e�-wave velocity (odds ratio, 1.35; P�0.047), and exercise-induced changes in indexed left atrial
area (odds ratio, 1.36; P�0.006). Ex-PHT was associated with reduced cardiac event-free survival (at 3 years, 22�7% versus
55�9%; P�0.014). In a multivariable Cox proportional hazards model, Ex-PHT was identified as an independent predictor
of cardiac events (hazard ratio, 1.8; 95% confidence interval, 1.0–3.3; P�0.047). When exercise-induced changes in mean
aortic pressure gradient were added to the multivariable model, Ex-PHT remained independently associated with reduced
cardiac event-free survival (hazard ratio, 2.0; 95% confidence interval, 1.1–3.6; P�0.025).
Conclusions—In asymptomatic patients with severe aortic stenosis, the main determinants of Ex-PHT are male sex, resting
systolic pulmonary arterial pressure, and exercise parameters of diastolic burden. Moreover, Ex-PHT is associated with
a 2-fold increased risk of cardiac events. These results strongly support the use of exercise stress echocardiography in
asymptomatic aortic stenosis. (Circulation. 2012;126:851-859.)
Key Words: aortic valve stenosis � exercise � echocardiography � heart valves � hypertension, pulmonary
The management and the timing of surgery in asymptomaticpatients with severe aortic stenosis (AS) remain matters of
concern. In this setting, valve replacement is recommended
when the left ventricular (LV) ejection fraction (LVEF) is
reduced (�50%). However, LVEF is often preserved in severe
AS as a result of adapted LV remodeling to the increased
afterload, often leading to late surgical referral. Furthermore,
recent studies have shown that irreversible LV myocardial
fibrosis may be present even when LVEF is preserved.1,2
Clinical Perspective on p????
A recent registry reported that compared with the conven-
tional treatment strategy (ie, wait for symptoms), early surgery in
patients with very severe AS was associated with an improved
long-term survival by decreasing cardiac mortality.3 However,
surgeons may be reluctant to operate on asymptomatic patients.
The risks of aortic valve surgery and late complications of
prosthesis need to be balanced against the possible prevention of
sudden death and lowering of cardiac mortality. Hence, early
elective surgery could be proposed to selected patients with a
high risk of rapid LV function deterioration or symptomatic
status impairment (ie, high risk of poor outcome).4,5 This
strategy requires the identification of accurate markers of poor
outcome. In this regard, the presence of pulmonary hypertension
(PHT) in patients with severe AS seems to be associated with a
poorer prognosis6,7 and a higher mortality rate after valve
replacement8 and represents an independent predictor of hospital
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mortality and postoperative major adverse cardiovascular and
cerebrovascular events.9 In patients receiving transcatheter aortic
valve implantation, PHT was a strong independent predictor of
poor outcome, augmenting by 2 the risk of late mortality.10
We have recently identified that exercise PHT in asymptom-
atic patients with primary mitral regurgitation was a good
marker of a high risk of reduced symptom-free survival. To the
best of our knowledge, the prognostic value of exercise PHT in
AS is still unknown. The aim of this study was to identify the
determinants and the potential prognostic importance of exercise
PHT in asymptomatic patients with severe AS.
Methods
We prospectively included consecutive patients with asymptomatic
severe AS (n�195), defined as an aortic valve area indexed for body
size area �0.6 cm2/m2, and preserved LVEF (�55%) who were
referred to our laboratory for exercise stress echocardiography. Only
patients with a normal exercise stress test (ie, truly asymptomatic
patients) were considered for the final analysis of the study, resulting
in the exclusion of 45 patients with abnormal exercise response. The
other exclusion criteria were (1) more than mild concomitant valvular
heart disease (n�3), (2) atrial fibrillation (n�2), (3) known pulmonary
disease (n�1), (4) inability to perform an exercise test (n�4), and (5)
the absence of measurable systolic pulmonary arterial pressure (SPAP)
at exercise (n�35). The final population was composed of 105 patients
(age, 71�9 years; male, 59%). The baseline demographic and clinical
data were standardized and collected at the time of exercise
stress echocardiography.
Echocardiographic Study
Before the exercise stress test, resting comprehensive transthoracic
echocardiography was performed with the VIVID 7 ultrasound system
(General Electric Healthcare, Little Chalfont, UK). All Doppler echo-
cardiographic recordings were stored on a dedicated workstation for
subsequent offline analysis. For each measurement, at least 2 cardiac
cycles were averaged. Continuous-wave Doppler was used to measure
the aortic transvalvular maximal velocities; peak and mean gradients
were calculated with the simplified Bernoulli equation (�P�4v2, where
v is maximal aortic velocity in meters per second). LV stroke volume
was calculated by multiplying the LV outflow tract area by the LV
outflow tract velocity–time integral measured by pulsed-wave Doppler.
Aortic valve area was calculated with the continuity equation. The
biapical Simpson disk method was applied to quantify LV end-diastolic
and end-systolic volumes and EF. In addition to this conventional
evaluation of LV systolic function, 2-dimensional speckle tracking
analysis (2-dimensional strain) was performed to quantify global longi-
tudinal myocardial deformation as previously described.5,11 Briefly,
2-dimensional strain is a non–Doppler-based method using standard
2-dimensional images with a frame rate acquisition�60 Hz. By tracing
the endocardial borders on an end-systolic frame, the software automat-
ically tracked the contour on the subsequent frames. Adequate tracking
was verified in real-time and was manually corrected when necessary.
The global longitudinal deformation strain represents the average of the
segment strains from the conventional apical 4-, 3-, and 2-chamber
views. Left atrial (LA) area was obtained by planimetry of an end-sys-
tolic frame from the apical 4-chamber view. Peak E- and A-wave
velocities of the mitral inflow were measured with pulsed-wave Dopp-
ler. Tissue Doppler imaging was applied for the measurement of the e�
wave. The average of septal and lateral mitral annulus Ea-wave
velocities was used to calculate the E/e� ratio.
SPAP was derived from the regurgitant jet of tricuspid regurgitation
using systolic transtricuspid pressure gradient and adding 10 mm Hg for
right atrial pressure as previously performed.12,13 Resting PHT and
exercise PHT were defined as SPAP �50 and �60 mm Hg, respec-
tively. Right atrial pressure was assumed to be constant from rest to
exercise.
Exercise Protocol
A symptom-limited graded maximum bicycle exercise test was
performed in the semisupine position on a tilt table. After an initial
workload of 25 W maintained for 2 minutes, the workload was
increased every 2 minutes by 25 W. A 12-lead ECG was monitored
continuously, and blood pressure was measured at rest and every 2
minutes during exercise. If patients were on �-blockers, they were
asked to stop their medication 24 hours before the test. The other
medications, if any, were left unchanged. Patients with an abnormal
exercise test were excluded from the present study. Abnormal
exercise test was defined as (1) the occurrence of limiting breath-
lessness or fatigue at low workload (�75 W); (2) the occurrence of
angina, dizziness, syncope, or near syncope; (3) a fall in systolic
blood pressure below baseline or a rise in systolic blood during
exercise�20 mm Hg; (4) �2-mm ST-segment depression compared
with baseline levels; and (5) complex ventricular arrhythmia.
Event-Free Survival
Follow-up information was obtained every 6 to 12 months from
standardized interviews with the patients, their physicians, or, if
necessary, their next of kin according to guidelines.14,15 The primary
outcome variable was the time to occurrence of the first composite
end point defined as cardiovascular death or need for aortic valve
replacement motivated by the development of symptoms or LV
systolic dysfunction. The patients’ personal physicians determined
the clinical management of the patients independently.
Statistical Analysis
Results are expressed as mean�SD or percentage unless otherwise
specified. Data comparisons were performed according to the pres-
ence or absence of exercise PHT using the Student unpaired t test, �2
test, or Fisher exact test as appropriate. The prevalence of PHT at rest
and during exercise was compared by use of McNemar test. The
significant changes from rest to exercise in continuous variables were
assessed with a paired t test. The relationships between exercise SPAP
and other continuous variables (ie, demographic data, exercise data, and
resting and exercise echocardiographic data) were evaluated by simple
linear regression. Independent predictors of exercise SPAP were ob-
tained with the use of stepwise multiple linear regression. Predictors of
exercise PHT were determined with stepwise logistic regression. In both
multiple linear regression and logistic regression, variables with a
univariable value of P�0.10 were incorporated into the multiple
regression; then, variables with a value of P�0.20 were removed.
Sensitivity, specificity, positive predictive value, and negative predictive
value for the prediction of the occurrence of cardiac event were
determined for various cutoff values of exercise SPAP with receiver-
operating characteristic curves.
Probabilities of event-free survival were obtained by Kaplan-
Meier estimates for the 2 groups and then compared by a 2-sided
log-rank test.
The impact of exercise PHT on event-free survival was assessed
with Cox proportional hazards models in univariable and multivari-
able analyses. Variables with a univariable value of P�0.10 were
incorporated into the multivariable models. The selection of vari-
ables included in the multivariate model was performed with special
care. To avoid collinearity among a subset of several variables
measuring the same phenomenon (eg, aortic valve area, peak
gradient, mean gradient), we entered into the multivariate models the
variable that had the strongest association with event-free survival on
univariable analysis. In addition, to assess the accuracy of the
prediction of a cardiac event by each model, we generated the Harrell
correspondence index (C statistic).
Values of P�0.05 were considered significant. All statistical
analyses were performed with STATISTICA version 7 (StatSoft Inc,
Tulsa, OK).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the manuscript
as written.
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Results
Population Characteristics
PHT, as previously defined, was significantly more frequent
during exercise (55% versus 6%; P�0.0001) than at rest.
Patients with exercise PHT were more frequently male and had
significant lower resting heart rate than those with no exercise
PHT (Table 1). In addition, all patients with resting PHT (n�6;
Table 2) also developed exercise PHT (P�0.027, resting PHT
prevalence in exercise PHT versus the no exercise PHT group).
There was no other significant difference between the 2 groups
in terms of demographic, clinical, or exercise data, as well as risk
factors and medications. The maximal exercise capacity reached
was 4.8�1.2 metabolic equivalents (METs; 64�14% of the
predicted METs), ranging from 2.3 to 8.6 METs with no
significant difference between the 2 groups (P�0.12 and
P�0.74 for the percentage of predicted METs).
Resting and Exercise Echocardiography
SPAP significantly increased from rest to exercise (from 38�8
to 62�16 mm Hg; P�0.0001). Patients with exercise PHT
had significant higher resting SPAP (P�0.0001; Table 2)
and exercise-induced changes in SPAP (14.9�7 versus
33.6�10 mm Hg; P�0.0001; Figure 1A and 1B). In patients
with exercise PHT, the mean relative change in SPAP was
121�61%. During exercise, SPAP was doubled in 10 patients
(21%) without exercise PHT and in 32 patients (56%;
P�0.0001) with exercise PHT.
Compared with patients with no exercise PHT, those with
exercise PHT (Table 2) had higher resting and exercise
indexed LV end-diastolic volume (P�0.045 and P�0.04)
and more severe resting and exercise AS (peak transaortic
gradient, P�0.046 and P�0.008; mean transaortic gradient,
P�0.04 and P�0.04), higher exercise e�-wave velocity
(P�0.004), and larger exercise indexed LA area (P�0.001).
There were also trends for significantly higher resting and
exercise E-wave velocity (P�0.10 and P�0.07) and exercise
indexed LV end-systolic volume (P�0.07).
Determinants of Exercise SPAP and PHT
In simple linear regression, exercise SPAP was significantly
correlated with resting SPAP (r�0.57, P�0.0001), heart rate
(r��0.20, P�0.045), E-wave velocity (r�0.19, P�0.05),
exercise e�-wave velocity (r�0.19, P�0.009), and indexed
LV end-diastolic volume (r�0.17, P�0.044). Both resting
and exercise peak (r�0.23, P�0.02; and r�0.29, P�0.003)
and mean (r�0.23, P�0.016; and r�0.24, P�0.013) transaortic
pressure gradients were significantly correlated with exercise
SPAP. In addition, the best correlation was found between
exercise SPAP and exercise-induced changes in indexed LA
area (r�0.40, P�0.0001). Multiple linear regression revealed
that the independent predictors of exercise SPAP were exercise
e�-wave velocity (��11�5; P�0.046), exercise indexed LV
end-diastolic volume (��0.14�0.07; P�0.038), resting SPAP
(��0.9�0.2; P�0.0001), and exercise-induced changes in in-
dexed LA area (��1.3�0.4; P�0.001).
On multivariable analysis, with logistic regression (Table
3), the independent predictors of exercise PHT were male sex
(odds ratio, 4.3; P�0.002), resting SPAP (odds ratio, 1.16;
P�0.002), exercise indexed LV end-diastolic volume (odds
ratio, 1.04; P�0.026), exercise e�-wave velocity (odds ratio,
Table 1. Demographic, Clinical, and Exercise Data
Variables
Whole Cohort
(n�105)
No Exercise PHT
(n�47, 45%)
Exercise PHT
(n�58, 55%) P
Demographic and clinical data
Age, y 71�9 71�7 71�9 0.77
Male sex, n (%) 62 (59) 23 (49) 39 (67) 0.03
Body surface area, m2 1.8�0.2 1.8�0.2 1.8�0.2 0.81
Heart rate, bpm 71�13 73�14 68�12 0.04
Systolic arterial pressure, mm Hg 142�20 139�19 144�20 0.13
Diastolic arterial pressure, mm Hg 76�11 76�12 77�10 0.64
Risk factors, n (%)
Hypertension 69 (66) 28 (60) 41 (71) 0.21
Overweight 36 (34) 15 (32) 21 (36) 0.68
Dyslipidemia 54 (51) 24 (51) 30 (52) 0.94
Diabetes mellitus 18 (17) 9 (19) 9 (16) 0.68
Smoker 35 (33) 14 (30) 21 (36) 0.63
LV hypertrophy 51 (49) 27 (57) 25 (43) 0.14
Exercise data
Maximal exercise capacity, METS 4.8�1.2 4.6�0.8 4.9�1.3 0.12
Percentage of predicted exercise capacity, % 64�14 64�12 63�15 0.74
Heart rate, bpm 119�17 118�17 119�17 0.62
Systolic arterial pressure, mm Hg 177�22 174�20 179�23 0.20
Diastolic arterial pressure, mm Hg 86�14 85�15 87�13 0.52
PHT indicates pulmonary arterial hypertension; LV, left ventricular; and MET, metabolic equivalents.
Lancellotti et al Exercise Pulmonary Hypertension in Asymptomatic AS 853
 by IMED Korea on November 5, 2012http://circ1ahajournals1org/Downloaded from 
121
1.35; P�0.047), and exercise-induced changes in indexed LA
area (odds ratio, 1.36; P�0.006).
Cardiac Event-Free Survival
The follow-up was complete in all patients (100%). The mean
follow-up time was 19�11 months (median, 16 months;
range, 2–48 months). During follow-up, 56 patients (53%)
fulfilled the predefined end point, resulting in event-free
survival of 72�4%, 50�5%, and 34�6% at the 1-, 2-, and
3-year follow-up, respectively. There were 7 cardiovascular
deaths during the follow-up (3 sudden deaths and 4 deaths
after heart failure hospitalization). Of note, the 7 patients who
died had developed exercise PHT (12%), but only 1 had
resting PHT (P�0.014). The remaining cardiac events were
aortic valve replacement dictated by the onset of symptoms
(n�49). The main indication for surgery was the occurrence
of syncope (n�4), angina (n�6), dyspnea (n�38), and
significant arrhythmia (n�1).
During the follow-up, among the 6 patients with resting
PHT, 1 died, 2 underwent an aortic valve replacement, and 3
remained free of event.
The raw rate of cardiac event (number of patients with an
event divided by total number of patients in each group) was
significantly higher in patients with exercise PHT (n�39
versus n�17, 67% versus 36%; P�0.0015).
Patients with exercise PHT had lower cardiac event-free
survival (at 1 year, 65�6% versus 81�6%; at 2 years, 43�7%
versus 59�8%; at 3 years, 22�7% versus 55�9%; P�0.014;
Table 2. Resting and Exercise Echocardiographic Data
Variables
Whole Cohort
(n�105)
No Exercise PHT
(n�47, 45%)
Exercise PHT
(n�58, 55%) P
Resting LV function
Indexed LV end-systolic volume, mL/m2 19�10 19�9 20�11 0.64
Indexed LV end-diastolic volume, mL/m2 54�17 51�15 57�18 0.045
LV ejection fraction, % 67�7.6 66�7.5 67.5�7.7 0.40
LV global longitudinal strain, % �16.3�2.6 �16.3�2.5 �16.2�2.7 0.82
E-wave velocity, cm/s 0.80�0.2 0.76�0.2 0.84�0.2 0.10
A-wave velocity, cm/s 0.93�0.3 0.89�0.3 0.97�0.3 0.23
e�-wave velocity, cm/s 7.8�2.2 7.6�1.8 8.0�2.5 0.35
E/A ratio 0.92�0.4 0.90�0.3 0.94�0.4 0.64
E/e� ratio 10.9�3.6 10.4�3.1 11.2�4.1 0.28
Exercise LV function
Indexed LV end-systolic volume, mL/m2 18�8.3 17�7.3 20�8.9 0.07
Indexed LV end-diastolic volume, mL/m2 54�17 50�15 57�19 0.04
LV ejection fraction, % 67�9 67�8 66�10 0.41
E-wave velocity, cm/s 1.27�0.3 1.22�0.3 1.33�0.3 0.07
A-wave velocity, cm/s 1.01�0.3 0.98�0.3 1.05�0.3 0.43
e�-wave velocity, cm/s 10.1�2.7 9.2�2.1 10.8�3.0 0.004
E/A ratio 1.35�0.6 1.25�0.4 1.44�0.8 0.25
E/e’ ratio 13.4�5.2 13.3�4.6 13.4�6.0 0.94
Resting aortic stenosis severity
Peak transaortic gradient, mm Hg 72�23 67�19 76�26 0.046
Mean transaortic gradient, mm Hg 45�15 42�12 47�16 0.04
Aortic valve area, cm2 0.89�0.1 0.88�0.1 0.90�0.1 0.59
Indexed aortic valve area, cm/m2 0.50�0.1 0.49�0.1 0.50�0.1 0.63
Exercise aortic stenosis severity
Peak transaortic gradient, mm Hg 91�28 83�21 97�31 0.008
Mean transaortic gradient, mm Hg 57�18 53�14 60�20 0.04
Aortic valve area, cm2 0.97�0.3 0.95�0.2 0.99�0.3 0.41
Indexed aortic valve area, cm/m2 0.54�0.16 0.53�0.1 0.55�0.2 0.46
Resting indexed LA area, cm2/m2 12.5�3.4 12.7�4 12.3�3 0.64
Exercise indexed LA area, cm2/m2 11.2�3.6 9.8�3.6 12.2�3.4 0.001
Resting PHT, n (%) 6 (6) 0 (0) 6 (10) 0.027
Resting SPAP, mm Hg 38�8 34�6 41�8 �0.0001
Exercise SPAP, mm Hg 62�16 48�9 74�9 �0.0001
PHT indicates pulmonary arterial hypertension; LV indicates left ventricular; LA, left atrial; and SPAP, systolic pulmonary arterial
pressure.
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Figure 2). In univariable analysis, exercise PHT was associated
with 2-fold increase in cardiac events compared with patients
without exercise PHT (P�0.017; Table 4). Other univariable
predictors of cardiac event were peak aortic jet velocity (hazard
ratio [HR], 2; 95% confidence interval [CI], 1.35–2.97;
P�0.001), mean aortic transvalvular gradient (HR, 1.03; 95%
CI, 1.01–1.04; P�0.02), LV filling time (HR, 1.01; 95% CI,
1.00–1.01; P�0.014), indexed LV end-systolic volume (HR,
1.03; 95% CI, 1.01–1.05; P�0.018), indexed LV end-diastolic
volume (HR, 1.02; 95% CI, 1.01–1.04; P�0.002), and indexed
LA area (HR, 1.06; 95% CI, 1.00–1.13; P�0.049). Of note,
exercise capacity, as assessed by the maximal reached METs,
was not associated with reduced cardiac-event free survival (HR,
1.83; 95% CI, 0.7–4.8; P�0.21), and none of the other exercise
parameters was associated with outcome.
Resting PHT (n�6) was not associated with reduced cardiac
event-free survival (P�0.37). However, there was a significant
relationship between resting SPAP and outcome (HR, 1.03; 95%
CI, 1.00–1.06; P�0.03). This relationship remained significant
after adjustment for age and sex (HR, 1.04; 95% CI, 1.00–1.07;
P�0.03) but not after adjustment for peak or mean aortic
transvalvular gradient (HR, 1.03; 95% CI, 0.99–1.06; P�0.135;
and HR, 1.03; 95% CI, 0.99–1.06; P�0.08, respectively).
Further adjustment with other resting echocardiographic data led
to a definite nonsignificant association between resting SPAP
and cardiac event-free survival (HR, 1.03; 95% CI, 0.99–1.07;
P�0.15).
After adjustment for age and sex, exercise PHT was indepen-
dently associated with reduced cardiac event-free survival (HR,
1.9; 95% CI, 1.1–3.4; P�0.025; Table 4). With further adjust-
ment including resting echocardiographic data, exercise PHT
remained independently associated with cardiac events (HR, 1.8;
95% CI, 1.0–3.3; P�0.047). As previously reported, exercise-
induced changes in mean transaortic pressure gradient were
associated with reduced event-free survival (HR, 1.02; 95% CI,
1.01–1.03; P�0.003). In the multivariable model (Table 4), after
adjustment for age, sex, resting echocardiographic data, and
exercise-induced changes in mean transvalvular pressure gradi-
ent, exercise PHT remained an independent predictor of high
risk of cardiac events (HR, 2.0; 95% CI, 1.1–3.6; P�0.025). Of
note, in this multivariable model, exercise-induced change in
mean transaortic pressure gradient was also an independent
predictor of events (P�0.043).
Figure 1. Impact of exercise on systolic pulmonary arterial pressure in patients without exercise pulmonary hypertension (A) and with
exercise pulmonary hypertension (B).
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Figure 2. Cardiac event-free survival according to the presence
or absence of exercise pulmonary hypertension (PHT).
Table 3. Logistic Regression: Independent Determinants of
Exercise Pulmonary Arterial Hypertension
Variables Odds Ratio 95% CI P
Male sex 4.3 1.2–15.1 0.002
Resting SPAP (per mm Hg) 1.16 1.06–1.27 0.002
Exercise indexed LV end-diastolic
volume (per mL/m2)
1.04 1.00–1.07 0.026
Exercise-induced changes in indexed
LA area (per cm2/m2)
1.36 1.1–1.7 0.006
Exercise e�-wave velocity (per cm/s) 1.35 1.00–1.8 0.047
CI indicates confidence interval; SPAP, systolic pulmonary arterial pressure;
LV, left ventricular; and LA, left atrial. Adjustment performed with age, resting
heart rate, resting mean transaortic pressure gradient, exercise peak transaor-
tic pressure gradient, exercise e�-wave velocity, and exercise indexed LV
end-systolic volume.
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Using receiver-operating characteristic curve analysis, we
found that exercise SPAP had a good accuracy for predicting
cardiac events (area under the curve, 0.69). Of interest, the
best cutoff value to predict cardiac events was exercise SPAP
�60 mm Hg: sensitivity, 70%; specificity, 62%; positive
predictive value, 67%; and negative predictive value, 64%.
In addition, to assess whether exercise SPAP was more
accurate than resting SPAP in predicting cardiac events, we
generated the C statistic for each model. The C statistics were
systematically higher with exercise SPAP than resting SPAP
in univariate age- and sex-adjusted or age-, sex-, and resting
echocardiographic data–adjusted models (0.610 versus 0.515,
0.613 versus 0.557, and 0.664 versus 0.611, respectively).
Incremental Prognostic Value of Exercise PHT
Over Resting AS Severity
In the whole multivariate model, peak aortic jet velocity was
the strongest resting echocardiographic predictor of outcome
(HR, 1.02; 95% CI, 1.01–1.03; P�0.0001). Figure 3 shows
the incremental value of exercise PHT over markedly elevated
peak aortic jet velocity (�4.0 m/s) in the prediction of cardiac
events. The combination of high peak aortic jet velocity and
exercise PHT resulted in the worse outcome (P�0.008). Com-
pared with the whole cohort, patients with high peak aortic jet
velocity and exercise PHT had a 2.4-fold increased risk of
reduced event-free survival (95% CI, 1.4–4.03; P�0.002).
Reducing the analysis only to the subset of patients with
markedly elevated peak aortic jet velocity resulted in a signifi-
cant impact of exercise PHT on outcome (HR, 2.4; 95% CI,
1.1–5.2; P�0.014). Of note, patients with exercise PHT but
without markedly elevated peak aortic jet velocity had a 2-year
event-free survival (54�10% versus 56�11%; P�0.77) similar
to that of patients with markedly elevated peak aortic jet velocity
but without exercise PHT. Furthermore, the 7 deaths occurring
during the follow-up were in patients with both markedly
elevated peak aortic jet velocity and exercise PHT (P�0.001).
Discussion
The main findings of the present study are that (1) exercise
PHT (ie, exercise SPAP �60 mm Hg) is a frequent condition
(55% of the cohort) in patients with asymptomatic severe AS
and preserved LVEF; (2) the independent determinants of
exercise PHT are male sex, resting SPAP, and exercise param-
eters of diastolic burden (exercise indexed LV end-diastolic
volume, exercise e�-wave velocity, and exercise-induced
changes in indexed LA area); (3) exercise PHT is associated
with an alarming rate of cardiac death (12%) and with significant
reduced cardiac event-free survival; (4) exercise PHT doubles
the risk of cardiac events independently of age, sex, resting
echocardiographic data, and exercise-induced changes in mean
transaortic pressure gradient; and (5) exercise PHT had an
incremental prognostic value compared with resting AS severity
parameter. Conversely, although resting elevated SPAP may
affect clinical outcome, its prognostic value was weak in our
study.
Pulmonary Arterial Hypertension in AS
The prevalence of PHT varies considerably over studies
according to patient selection criteria and the threshold used
to define PHT. Overall, an SPAP �50 mm Hg is found in
15% to 30% of patients with severe AS,16–18 and recently,
severe SPAP (�60mmHg) was reported in 19% of a large
cohort of 626 AS patients.19
Table 4. Cox Proportional Hazards Regression Analysis for
the Prediction of Cardiac Event-Free Survival
Models
Exercise PHT
Hazard Ratio 95% CI P
Univariable 2.0 1.1–3.5 0.017
Age and sex adjusted 1.9 1.1–3.4 0.025
Resting data adjusted* 1.8 1.1–3.3 0.045
Exercise data adjusted† 2.0 1.1–3.6 0.025
PHT indicates pulmonary arterial hypertension; CI, confidence interval.
*Adjustment including age, sex, indexed left atrial area, left ventricular
end-systolic volume, left ventricular end-diastolic volume, E/e� ratio, and peak
aortic jet velocity.
†Adjustment including age, sex, resting echocardiographic data, and
exercise-induced changes in mean transaortic pressure gradient.
Figure 3. Cardiac event-free survival according to
the presence or absence of exercise pulmonary
hypertension (Ex. PHT) and markedly elevated
peak aortic (Ao) jet velocity (�4 m/s).
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However, to the best of our knowledge, no study has
reported the prevalence of PHT in truly asymptomatic pa-
tients. In our cohort, an SPAP �50 mm Hg was rare and
identified in only 6 patients (6%), suggesting that the impact
of severe AS on LV diastolic function20 and LA geometry and
function21,22 may be generally well counterbalanced by LA
compliance and/or pulmonary vascular resistance. Of interest,
these patients with resting PHT were particularly old and had
very severe AS, and half of them experienced cardiac events
(including 1 death and 2 aortic valve replacement), suggest-
ing the poor outcome of this subset. In contrast, a recent study
has shown that PHT is frequent in surgery-referred patients
with LV dysfunction and is independently associated with LA
function impairment.23
The potential impact on outcome of PHT in patients with
AS is also a source of debate. In 1979, McHenry et al7
showed that PHT could be considered a harbinger for sudden
death and clinical deterioration. More recently, PHT in severe
AS was also associated with a dismal prognosis under
conservative management.24,25 Nevertheless, PHT may fre-
quently and rapidly be abolished after aortic valve replace-
ment,24–26 leading to a more favorable long-term outcome.27
Exercise PHT in AS
Exercise PHT was significantly more frequent (55%) than
resting PHT (6%) in our cohort. This entity is characterized
by lower resting heart rate and higher resting and peak
exercise indexed LV end-diastolic volume. During exercise,
whereas some patients with no exercise PHT may have only
a mild increase in SPAP (Figure 1A), the vast majority of
those with exercise PHT (Figure 1B) experienced a marked
rise in SPAP. This phenomenon is essentially determined by
the level of exercise e�-wave velocity, the exercise indexed
LV end-diastolic volume, and the exercise-induced changes
in indexed LA area.
In AS, the chronically increased afterload results in progres-
sive LV remodeling and myocardial hypertrophy. Although the
increase in LV wall thickness is a compensatory mechanism that
reduces systolic wall stress, it can result in impaired LV
relaxation, reduced LV compliance, and increased metabolic
demands. The ability of the LV to adequately fill under normal
pressures is thus altered and the LV diastolic pressure increases.
As a result, LA slowly expands and becomes dysfunctional and
less compliant, making it impossible to limit the transmission to
the pulmonary vascular bed of any further increase, even
minimal, in LV end-diastolic pressure observed during exercise.
Furthermore, any degree of LV diastolic dysfunction (relaxation
abnormality) and increased LV filling pressure at rest and/or at
exercise can be sufficient to trigger exercise PHT. In these
patients, exercise echocardiography enables us to unmask a
more advanced impairment in LV diastolic properties, namely
latent LV diastolic dysfunction. This is line with our observa-
tions because exercise PHT was related mainly to exercise
parameters of diastolic burden. Of note, a limitation in LA
compliance was confirmed by the significant correlation ob-
served between exercise-induced changes in indexed LA area
and exercise SPAP. For a given increase in LV filling pressure,
patients with limited changes in LA dimensions (ie, exhausted
LA compliance reserve) during exercise displayed a higher
increase in SPAP; this is even truer if LA emptying is not
facilitated any more from recruitable LA function.
Clinical Implications
Our results are the first to demonstrate that the measurement
of SPAP during exercise echocardiography may improve risk
stratification of asymptomatic severe AS. Indeed, patients who
experienced exercise PHT (SPAP�60 mm Hg) multiplied by 2
the risk of cardiac events, even after adjustment for demographic
and resting and exercise echocardiographic data. Among the 7
cardiovascular-related deaths that occurred during follow-up,
only 1 patient had resting PHT, but all of those patients had
developed exercise PHT. Of interest, our data show that resting
elevated SPAP is not independently associated with reduced
cardiac event-free survival in “truly” asymptomatic patients with
severe AS.
Hence, these results strongly emphasize the usefulness of
exercise stress echocardiography in this clinical situation. Exer-
cise PHT also had incremental prognostic value compared with
AS severity parameters (ie, aortic jet velocity). Indeed, in
patients with markedly elevated aortic jet velocity, those with
exercise PHT exhibited a significant lower cardiac event-free
survival (Figure 3) compared with the others, resulting in poorer
outcome. Furthermore, patients with exercise PHT but without
markedly elevated aortic jet velocity had a prognosis similar to
that for those without exercise PHT but with high aortic jet
velocity. Thus, in patients with asymptomatic AS and �4-m/s
aortic jet velocity, the presence of exercise PHT is still able to
identify a subset of patients at dismal prognosis (Figure 3) who
may require a closer follow-up to look for any changes in LV
diastolic function and symptoms.
During tests, an exercise-induced increase in mean transaortic
pressure gradient by �18 to 20 mm Hg has recently been
identified as a marker of poor prognosis in asymptomatic
AS.28,29 Our results confirm that this parameter is associated
with reduced cardiac event-free survival, but we further show
that exercise PHT is an predictor of impaired prognosis inde-
pendently of the changes in LV afterload. Interestingly, only one
third of patients with exercise PHT also had a marked increase
in mean transaortic pressure gradient. This suggests that the
presence of elevated exercise SPAP may unmask a subset of
asymptomatic patients with latent LV diastolic dysfunction,
reduced atrioventricular compliance, and impaired pulmonary
vascular resistance. These patients are probably more subject to
rapidly developing symptoms and seem to be at higher risk of
cardiac-related death. Consequently, the use of exercise stress
echocardiography in asymptomatic patients with severe AS
could be recommended. At peak exercise, the measurement of
both mean transaortic pressure gradient and SPAP, which are
technically easy and rapid and have good reproducibility,13,29–32
may improve the management of such patients. Indeed, the high
rate of cardiac-related death observed in patients with exercise
PHT (12%), despite normal exercise tests, should encourage
prompt surgery, which is, in asymptomatic patients, associated
with very low operative mortality3 and low prosthesis-related
complication rate. Conversely, patients with no exercise PHT
and no marked increase in mean transaortic gradient can be
followed up safely.
Lancellotti et al Exercise Pulmonary Hypertension in Asymptomatic AS 857
 by IMED Korea on November 5, 2012http://circ1ahajournals1org/Downloaded from 
125
Limitations
Apparent nonsignificant results may be related to the relatively
small sample size of the study. Specifically, the absence of
relationship between maximal exercise capacity parameters and
cardiac event-free survival could be due mainly to a type II error.
Nevertheless, this limitation does not affect the validity of the
main result of the study, which is the demonstration that exercise
PHT may have an incremental prognostic value in patients with
asymptomatic severe AS.
Despite careful assessment, the evaluation of the occur-
rence of symptoms at a low workload during exercise remains
subjective. Hence, although rare, it is possible that some
patients with symptoms during exertion were included in the
final population.
As in our previous studies,13,33 the right atrial pressure was
estimated at 10 mm Hg both at rest and during exercise.
Hence, we may have missed the potential influence of
exercise-induced changes in right atrial pressure. Neverthe-
less, the noninvasive evaluation of right atrial pressure during
exercise (ie, when venous compliance is known to decrease)
with noninvasive methods such as Doppler echocardiography
remains difficult, is probably subject to low accuracy, and is
not validated. Moreover, right atrial pressure is frequently
assumed to be 5 mm Hg in normal subjects30 and 10 mm Hg
in patients with valvular disease.12
The absence of evaluation of the presence and extent of
coronary artery disease in patients not referred to surgery is
also a limitation of this report. However, these patients have,
by definition, no resting symptoms and normal LVEF and
exercise test, suggesting that they are truly asymptomatic. In
this context, coronary angiography is not recommended, and
the rate of significant coronary artery disease in our popula-
tion is probably low.
Conclusions
In asymptomatic patients with severe AS, the main determinants
of exercise PHT are male sex, resting SPAP, and exercise
parameters of diastolic burden. Exercise PHT is associated with
a 2-fold increased risk of cardiac events and provides incremen-
tal prognostic value independently of demographic, resting
echocardiographic data, and exercise-induced changes in mean
transaortic pressure gradient. These results support the use of
exercise stress echocardiography in asymptomatic AS.
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CLINICAL PERSPECTIVE
The management and timing of surgery in asymptomatic patients with severe aortic stenosis remain matters of concern. The
risks of aortic valve surgery and late complications of prosthesis in such patients need to be balanced against the possible
prevention of sudden death and lowering of cardiac mortality. Hence, early elective surgery could be proposed only to
well-selected patients considered at high risk of poor outcome. In the present study, 105 consecutive asymptomatic patients
with severe aortic stenosis underwent comprehensive resting and exercise stress echocardiography to evaluate the presence
of pulmonary hypertension (PHT). The results showed that 55% of asymptomatic patients may develop exercise PHT.
Patients with exercise PHT had significantly lower cardiac event-free survival and a markedly higher rate of death than
those without exercise PHT. In addition, exercise PHT was associated with poorer outcome independently of demographic
and resting echocardiographic data and exercise-induced changes in mean transaortic pressure gradient. Beyond both
resting aortic stenosis severity and systolic pulmonary arterial pressure, the assessment of the presence of exercise PHT
provided important incremental predictive value. Even in patients with markedly elevated aortic jet velocity, those with
exercise PHT depicted a higher risk of reduced cardiac event-free survival. These results strongly support the use of
exercise stress echocardiography in the management of asymptomatic severe aortic stenosis. Early elective aortic valve
surgery to prevent irreversible left ventricular myocardial damage, diastolic dysfunction, and symptoms could be advised
in patients developing exercise PHT. In contrast, asymptomatic patients with no exercise PHT may be conservatively
followed up.
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